TYK MEDICINES-B (02410.HK): First Kadasa Batch Due 18 November, Shipping by Month-End

NewTimeSpace News: On 11 November 2026, TYK Medicines, Inc (stock code: 2410) published a voluntary announcement on commercial progress of its core product Kadasa (TY-9591), which received conditional approval from China's National Medical Products Administration on 27 August 2026 for first-line treatment of adults with locally advanced or metastatic non-small cell lung cancer harbouring EGFR exon 19 deletion or exon 21 (L858R) substitution mutations and central nervous system metastases.

The first batch of Kadasa is expected to complete production on 18 November 2026, and by the end of November the first commercial shipments are expected to reach first-tier distributors designated by Qilu Pharmaceutical (Hainan) Co., Ltd. Qilu is expected to launch academic promotion on 13 November 2026, marking the formal start of commercial sales and prescribing in China. The Company will continue to work with Qilu to commercialise Kadasa under the licence and cooperation agreement and the supply and commercialisation agreement set out in announcements dated 21 July and 11 November 2026.

Kadasa is a highly selective, irreversible EGFR-TKI developed in-house. Its favourable pharmacokinetics significantly reduce the generation of toxic metabolites, with particularly strong efficacy in patients with brain metastases and the L858R mutation; beyond monotherapy, a combination with chemotherapy is preparing to enter a registrational trial. The Company cautioned that it cannot guarantee successful commercialisation.